Matched FF and FFPE WGS from a metastatic prostate tumor
This dataset contains three bam files. One normal blood sample and two matched FF and FFPE samples from the same metastatic prostate tumor.
- 3 samples
- DAC: EGAC00001001608
- Technology: HiSeq X Ten
- GRU-CC DUO:0000005 (version: 2019-01-07)general research use and clinical careThis data use limitation indicates that use is allowed for health/medical/biomedical purposes and other biological research, including the study of population origins or ancestry.
- RU DUO:0000014 (version: 2019-01-07)research use onlyThis data use limitation indicates that use is limited to research purposes (e.g., does not include its use in clinical care).
- PUB DUO:0000019 (version: 2019-01-07)publication requiredThis data use modifier indicates that requestor agrees to make results of studies using the data available to the larger scientific community.
- US DUO:0000026 (version: 2019-01-07)user specific restrictionThis data use modifier indicates that use is limited to use by approved users.
- IS DUO:0000028 (version: 2019-01-07)institution specific restrictionThis data use modifier indicates that use is limited to use within an approved institution.
Data Access Agreement Policy for the metastatic prostate samples from the UZ Ghent.
DATA ACCESS AGREEMENT UNIVERSITY HOSPITAL GHENT - part of Ghent University, in accordance with the Special Decree of June 26th, 1991 (Belgian Official Gazette 29/6/1991) with registered office in Belgium, 9000 Ghent , Sint – Pietersnieuwstraat 25, registration number 0248.015.142, and with head office in Belgium, 9000 Ghent Corneel Heymanslaan 10, (VAT number: BE0232.987.862) with regard to this agreement duly represented by Prof. dr. E. Mortier, executive director who assigns the further execution of the Agreement to ptof. dr. Piet Ost as Provider (hereinafter referred to as “Provider”); [AND] Xxxxxxxxxx, (hereinafter referred to as “User”) Xxxxxxxxxx, (hereinafter referred to as “User Institution”) This agreement governs the terms on which access will be granted to the genotype data generated by Provider and transferred through Provider to the EGA database. The access rights are defined below by the Provider. In signing this agreement, You are agreeing to be bound by the terms and conditions of access set out in this agreement. For the sake of clarity, the terms of access set out in this agreement apply both to the User and the User’s Institution (as defined below). User Institution and User are referred to within the agreement as “You” and “Your” shall be construed accordingly. Definitions: Data means all and any human genetic data obtained from the Provider. Data Subject means a person, who has been informed of the purpose for which the Data is held and has given his/her informed consent thereto. User means a researcher whose User Institution has completed this Data Access Agreement and has received acknowledgement of its acceptance. Publications means, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. User Institution means the organisation at which the User is employed, affiliated or enrolled. Terms and Conditions: In signing this Agreement: 1. You agree to use the Data only for the advancement of medical research, according to the consent obtained from sample donors. 2. You agree to preserve, at all times, the confidentiality of information and Data pertaining to Data Subjects. In particular, You undertake not to use, or attempt to use the Data to compromise or otherwise infringe the confidentiality of information on Data Subjects and their right to privacy. 3. You agree not to attempt to link the data provided under this agreement to other information or archive data available for the data sets provided, even if access to that data has been formally granted to you, or it is freely available without restriction, without specific permission being sought from the relevant access committees. 4. You agree not to transfer or disclose the Data, in whole or part, or any identifiable material derived from the Data, to others, except as necessary for data/safety monitoring or programme management. Should You wish to share the Data with a collaborator outwith the same Institution, the third party must make a separate application for access to the Data. 5. You agree to use the data for the approved purpose and project described in your application; use of the data for a new purpose or project will require a new application and approval. 6. You accept that Data will be reissued from time to time, with suitable versioning. If the reissue is at the request of sample donors and/or other ethical scrutiny, You will destroy earlier versions of the Data. 7. You agree to abide by the terms outlined by the Provider in Schedule 1. 8. You agree to acknowledge in any work based in whole or part on the Data, the published paper from which the Data derives, the version of the data, and the role of the Provider and the relevant primary collectors and their funders. Suitable wording is provided in the Publications Policy given in Schedule 1. 9. You accept that the Provider, the original data creators, depositors or copyright holders, or the funders of the Data or any part of the Data supplied: a) bear no legal responsibility for the accuracy or comprehensiveness of the Data; and b) accept no liability for indirect, consequential, or incidental, damages or losses arising from use of the Data, or from the unavailability of, or break in access to, the Data for whatever reason. 10. You understand and acknowledge that the Data is protected by copyright and other intellectual property rights, and that duplication, except as reasonably required to carry out Your research with the Data, or sale of all or part of the Data on any media is not permitted. 11. You recognize that nothing in this agreement shall operate to transfer to the User Institution any intellectual property rights relating to the Data. The User Institution has the right to develop intellectual property based on comparisons with their own data. 12. You accept that this agreement will terminate immediately upon any breach of this agreement by You and You will be required to destroy any Data held. 13. You accept that it may be necessary for the Provider or its appointed agent to alter the terms of this agreement from time to time in order to address new concerns. In this event, the Provider or its appointed agent will contact You to inform You of any changes and You agree that Your continued use of the Data shall be dependent on the parties entering into a new version of the Agreement. 14. You agree that you will submit a report to the Provider Data Access Committee, if requested, on completion of the agreed purpose. The Provider Data Access Committee agrees to treat the report and all information, data, results, and conclusions contained within such report as confidential information belonging to the User Institution. 15. You accept that the Data is protected by and subject to national and international laws, including but not limited to the General Data Protection Regulation (EU) 2016/679 (GDPR) and that You are responsible for ensuring compliance with any such applicable law. The Provider Data Access Committee reserves the right to request and inspect data security and management documentation to ensure the adequacy of data protection measures in countries that have no applicable laws comparable to that which pertain in the EAA. 16. This agreement shall be construed, interpreted and governed by the laws of and shall be subject to the rules of Belgium, located with its headquarters in Brussels. SCHEDULE 1 Publications Policy The primary purpose of the data owners is to accelerate efforts to identify genome sequence variants influencing major causes of prostate cancer. This includes the development and validation of informatics and analytical solutions. Authors who use data from the project must acknowledge the original authors in their publications using the following wording "This study makes use of data generated by the UZGhent. The authors should cite the relevant primary publication in which this dataset was first used (de Schaetzen van Brienen et al., BMC Medical Genomics 2020). Users should note that the data owners bear no responsibility for the further analysis or interpretation of these data, over and above that published by themselves. For and on behalf of User: Name of Applicant(s): Signature of Applicant(s): Date: For and on behalf of User Institution: Signature of Institutional or Administrative Authority: Print name: User Institution: Date: For and on behalf of Provider: Name of Provider(s): Signature of Provider(s): Date: WHEN SUBMITTING THIS DOCUMENT, PLEASE INCLUDE ALL PAGES OF THE AGREEMENT WITH THIS SIGNATURE PAGE
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS00001004456 | Other |